What if the solutions to the greatest unsolved medical problems of our time had already been evolved in nature, hiding in plain sight as molecules waiting to be mined?
What if revolutionary discoveries in emerging scientific fields from gigascale DNA sequencing to artificial intelligence and synthetic biology had advanced, such that we finally had a way to mine the biosphere and bring transformative new medicines to patients in need?
Our answers to these questions drive the passion and mission at LifeMine Therapeutics.
LifeMine is reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere. Our integrated, evolution-derived, AI- and genomically-enabled drug discovery engine is poised to deliver a pipeline of novel medicines that will conquer previously unconquerable human diseases.
The company has succeeded in hacking an evolutionary code in biosynthetic genes, creating a springboard for rapid discovery of naturally inspired drugs that function in unexpected ways. These medicines transcend the standard playbook of drug design.
LifeMine grew out of visionary founder Gregory Verdine’s life passion to discover and commercialize new drug modalities.
LifeMine has amassed a virtually limitless amount of natural biological space to digitally search for new drugs – consisting of a fully curated fungal genome repository of an unprecedented scale. Given their evolutionary proximity to humans, fungi have long been an important source of radically impactful medicines. Drugs derived from fungi often target the same protein in fungi and humans – in fact, fungi are prodigious manufacturers of genetically-encoded small molecules (GEMs) that engage human targets. As such, fungi act as “avatars” to find small molecule therapeutic solutions for human diseases. But discovering these GEMs has heretofore been fraught with difficulty, leaving the precious GEMs just beyond reach. Enter LifeMine, with an entirely new way to discover GEMs, by searching for them algorithmically in genomic space rather than physically in chemical space.
LifeMine’s Avatar-Rx platform seamlessly integrates high-throughput microbiology, data science and machine learning, genome engineering and automation technologies to search the fungal biosphere for novel GEMs having a predetermined target and biological function. Downstream of GEM discovery, LifeMine’s platform further integrates chemoinformatic-assisted drug optimization and state-of-the art chemical synthesis with biotransformation to advance new product candidates into development.
Through our approach, we aim to bring unparalleled speed, predictability and scalability to small molecule drug discovery, offering the potential to rapidly advance multiple high-impact precision medicines to solve intractable disease challenges, irrespective of therapeutic area.
If you love working with the best people in the field, expanding your limits, and want to write the future story of medicine, then come join our team at LifeMine.
Press Releases
LifeMine Therapeutics Appoints Jennifer A. Jarrett to Board of Directors
Fierce Biotech names LifeMine Therapeutics as one of its “Fierce 15” Biotech Companies of 2022
LifeMine Therapeutics and GSK Enter Drug Discovery and Development Alliance
LifeMine Therapeutics Announces $175 Million Series C Financing
LifeMine Therapeutics Appoints Nobel Laureate William G. Kaelin Jr., M.D., to Board of Directors
LifeMine Therapeutics Announces $50 Million Series B Financing
LifeMine Powers Drug Discovery Team to Search the Biosphere for Nature’s Evolved Solutions to Intractable Therapeutic Challenges
LifeMine Therapeutics Launches with $55 Million Series A Financing
In the News
Boston Globe: Top 50 medium-size employers in Massachusetts for 2022
Fierce Biotech: 2022 Fierce 15
Fierce Next Gen: Biopharma begins to hand AI the keys to the research car
Switzerland Global Enterprise: Basel Area Achieves Milestone with Settling of LifeMine
Boston Business Journal: With $175M, GSK partnership, LifeMine eyes fungi as future of drugmaking
BioPharma Dive: GSK partners with LifeMine as startups advance plans to make drugs from fungi
Media Contact:
media@lifeminetx.com
617.665.5000